TrialCancer2016

A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Antonio Jimeno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.